For the Inventor, By the Inventor

Enter assignee name

Frankfurt, Germany

Aeterna Zentaris Gmbh

Calculating rank

USPTO Granted Patents = 36

% Expired Patents = 86.1

CIPO Patents = 1

EPO Patents = 2

Trademarks = 3

Forward Citations = 106

Loading Chart...

Loading Chart...

59 inventors (with patents filed for the assignee):

Eckhard Guenther (12 out of 16 patents)

Irene Seipelt (11 out of 13 patents)

Eckhard Günther (11 out of 23 patents)

4. Tilmann Schuster (10 out of 14 patents)

5. Matthias Gerlach (10 out of 31 patents)

6. Emmanuel Polymeropoulos (9 out of 24 patents)

7. Eckhard Claus (8 out of 11 patents)

8. Michael Teifel (7 out of 12 patents)

9. Jürgen Engel (6 out of 10 patents)

10. Klaus Paulini (6 out of 8 patents)

11. Herbert Sindermann (5 out of 5 patents)

12. Gilbert Mueller (4 out of 4 patents)

13. Ulf R Rapp (4 out of 6 patents)

14. Peter Schmidt (4 out of 7 patents)

15. Silke Baasner (3 out of 11 patents)

Core Competencies:

Growth Hormone Deficiency

LHRH Antagonists

Kinase Inhibitors

Pyridopyrazine Derivatives

Cancer Therapy

Signal Transduction

G-Protein Coupled Receptors

Antimetabolites

Indole Derivatives

Pharmaceutical Kits

Oncoses Treatment

Bioavailability

36 patents: Sort by Forward Citations

1. 10288629 - Method of assessing growth hormone deficiency in humans by a macimorelin containing composition (2019-05-14),

2. 8921318 - Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits (2014-12-30),

3. 8912189 - Pyridopyrazine derivatives and their use (2014-12-16),

4. 8791118 - Pyridopyrazines as highly selective ras-Raf-Mek-Erk signal transduction pathway inhibitors (2014-07-29),

5. 8679473 - Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof (2014-03-25),

6. 8658615 - Prohibitin as target for cancer therapy (2014-02-25),

7. 8604196 - Modulating signal transduction pathways with 1-ethyl-3-[3-(1-methyl-1H-pyrazol-4-yl)-pyrido[2.3-B]pyrazine-6-yl]thiourea (2013-12-10),

8. 8551977 - Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals (2013-10-08),

9. 8546435 - Triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors (2013-10-01),

10. 8541462 - Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors (2013-09-24),

11. 8536332 - Modulating signal transduction pathways with substituted pyridol [2,3-b] pyrazines (2013-09-17),

12. 8507710 - Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals (2013-08-13),

13. 8507486 - Pyridopyrazine derivatives, process of manufacturing and uses thereof (2013-08-13),

14. 8470776 - Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof (2013-06-25),

15. 8461178 - Naphthyridine derivatives and the use thereof as kinase inhibitors (2013-06-11),

Company Overview

Aeterna Zentaris GmbH is a biopharmaceutical company based in Frankfurt, Germany, specializing in the development of innovative therapeutics for oncology and endocrinology. The organization focuses on advancing its proprietary drug candidates through clinical development, aiming to address unmet medical needs in various therapeutic areas. With a commitment to research and development, Aeterna Zentaris leverages its expertise to explore novel treatment options and improve patient outcomes in the global healthcare landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

36 Patents

#32 in Frankfurt

#1,401 in Germany

#18,777 in the World

Frankfurt, Germany

Aeterna Zentaris Gmbh

Forward Citations = 106

59 inventors:

Eckhard Guenther (12 out of 16 patents)

Irene Seipelt (11 out of 13 patents)

Eckhard Günther (11 out of 23 patents)

4. Tilmann Schuster (10 out of 14 patents)

5. Matthias Gerlach (10 out of 31 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Aeterna Zentaris Gmbh. Retrieved from https://idiyas.com/company/aeterna-zentaris

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…